November 14, 2011
Ono Pharmaceutical announced on November 14 that KAI Pharmaceuticals, Inc. (South San Francisco, the US) has announced positive results from a PII clinical trial of ONO-5163/KAI-4169, a calcium receptor agonist being studied in end-stage renal disease (ESRD) patients on hemodialysis...read more